Private equity is selling insurers the exit it cannot find

A buyout fund that cannot sell the companies it owns can still sell a slice of the fund, and the slice it is selling hardest is the piece an insurance general account is allowed to hold. Private equity has a cash problem: exits have slowed, portfolio companies are sitting on sponsors' books, and investors who committed years ago are still waiting to get their money back; the relief valve dealmakers have found sits on the other side of the industry, the balance sheets of insurance companies.

The mechanism is structured debt that carves a pool of assets into tranches, each priced to a different tolerance for loss: the top slice is paid first and carries the least risk, the bottom absorbs losses first and pays the most. That split makes the trade work across two very different buyers, an insurer taking only the safest portion of the pool while a hedge fund or private credit manager takes the riskier end in exchange for a larger return.

The shape will look familiar to anyone who remembers 2008, and the article draws the comparison itself: this is the same idea that sat underneath mortgage-backed securities, with stakes in aging buyout funds standing in for home loans. What differs is what sits inside the pool — a fund stake is a claim on a portfolio the sponsor controls and decides when, or whether, to sell.

Collateralized fund obligations are the older of the two structures driving the trend: stakes in buyout funds are pooled and bonds issued against the pool. The technique has existed for two decades, but it has lately found a far bigger audience — Insurance Business America, relaying KBRA's published research, counts 152 tranches across 67 deals between 2018 and 2024 worth $37.7 billion, and by September 2025 KBRA-rated CFO volume hit a record $16 billion, enough in one year to outstrip the prior seven years combined.

Two of the biggest names in the secondaries business, where funds buy up existing stakes in other private equity vehicles, have recently gone to market with CFOs of their own, and the article reports Blackstone was exploring a sale in June 2026. When the largest sponsors in the market are packaging fund stakes rather than selling companies, what they are really doing is changing the shape of the asset until a new class of buyer can hold it.

Insurers are a natural target for that effort, because the general account needs yield and the private credit build-out across life balance sheets has been the industry's answer for several years. The same publication ran a Moody's warning that US life insurers' private credit push is creating liquidity and concentration risks, a caution that lands directly on structures like these, which concentrate exposure to a single underlying variable: how fast private equity can get out of its positions.

Net asset value loans are the second structure, and they work by letting a fund borrow against the value of its own holdings rather than selling them, returning cash to investors or funding fresh purchases without a full exit — exactly the trade a sponsor wants when the exit door is narrow. Managers have now started tranching these loans as well, carving out senior portions rated highly enough to reach insurers and junior portions pitched at private credit firms with more appetite for risk.

Thomas Speller, co-head of funds ratings at Kroll Bond Rating Agency, told the Financial Times that this kind of structuring had picked up noticeably over the past year as issuers seek buyers with different risk tolerances, according to the article's account.

The NAV tranche is the one that changes the map, because a CFO merely repackages stakes that already existed and would have found a buyer somewhere, whereas a tranched NAV loan turns a fund's unrealized marks into a rated instrument and gives a general account a way into a slice of private markets it could not previously reach directly. That is the difference between moving an existing trade to a new buyer and building an asset class with an insurance bid sitting underneath it.

A top tranche is marketed as credit risk, and the label is imprecise: the senior slice of a CFO or a tranched NAV loan gets paid first out of whatever the underlying fund stakes distribute, and the cash to pay it has to come from the same exits that have slowed to a crawl. Seniority in these structures is a claim on the order of payment, which means that at the top of the stack an insurer is underwriting less the borrower's capacity to repay than the timing of a market the borrower does not control.

That timing cuts in both directions, and neither one is the exposure a spread table implies. Slow exits keep the paper outstanding and the coupon flowing, which looks fine right up until the market reopens and the top tranche amortizes, handing the general account its money back to reinvest at whatever spread is left. A reopened exit market is the sponsor's good news and the senior buyer's problem, exactly the reverse of how these deals are usually discussed; the point does not depend on a wave of defaults, only on the exit calendar, and no tranche holder can hedge that.

The appetite for that trade is easy to understand: a life company with long-dated liabilities can hold a slow-amortizing senior position through a soft stretch in exits without much strain, which is precisely why the structures are built to reach it. The difficulty is equally plain — a book that has to meet claims on a shorter schedule has less room, and the buyer mix these deals are designed to produce, insurers at the top and hedge funds and private credit at the bottom, reflects that division of labor rather than any illusion about the risk at either end.

The NAIC's risk-based capital rewrite is now a live pricing event, and this is exactly the paper it prices: a tranche rated highly enough to appeal to an insurer still has to clear the SVO's designation and the capital charge that follows it, and deals being structured this quarter are being priced against a formula that is still being written. The structures are moving faster than the rules, and the general accounts holding the top slices are the ones carrying that gap.

Seen from the sponsor's side, this is the annexation of insurance by asset managers in its most technical form: no acquisition, no reinsurance treaty, no sidecar, just a rated instrument sold into the general account, the flow-partnering channel alternative managers have been developing for years, executed one tranche at a time. The difference is that earlier versions of that channel gave the manager a captive buyer, while this one gives it a buyer with a capital charge, a designation process, and a duration it has to match.

The traffic does not all run one way, and the archive makes the point: Fidelis Partnership cut the spread on its debt by 225 basis points this summer with a $2.04 billion term loan B, replacing a private-credit unitranche with a cheaper public loan and saving roughly $46 million a year to fund Lloyd's and Pine Walk growth, as this publication reported. Borrowers that can reach the broadly syndicated market at a better price will take it, which is the same calculation now sending sponsors toward insurance capital, run in the opposite direction; private credit's cost advantage over public markets is what is being repriced on both sides of this trade, and insurance money is a participant rather than a bystander.

The number worth watching is the spread between the senior and junior slices on the next NAV tranche to come to market, and the exit calendar behind it. If the junior end has to cheapen to clear, the insurance bid the whole structure exists to reach is thinner than the deal count suggests; if the exit market reopens first, the senior buyers get their money back at the moment they can do least with it.